← back to search

David E. Timm

Eli Lilly (United States) · US
Area of research
Materials Chemistry · Computational Theory and Mathematics
Research interest
Research interests include Enzyme Structure and Function, Computational Drug Discovery Methods, Metabolism and Genetic Disorders, and Protein Structure and Dynamics.
h-index
33
citations
3,247
works
87
NIH funding
primary concept
email

Recent publications

Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction
Journal of Medicinal Chemistry 2021cited by 52position: middledoi
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor
Journal of Medicinal Chemistry 2021cited by 27position: middledoi
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans
Journal of Neuroscience 2015cited by 205position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 1 papers (2021–2021) · 1 papers (2021–2021)Matthew J. Ranaghan · University of Connecticut1 papers (2021–2021) · 1 papers (2021–2021)Kathleen M. Mulvaney · Virginia Tech1 papers (2021–2021) · 1 papers (2021–2021)Arthur J. Campbell · Massachusetts Institute of Technology1 papers (2021–2021) · 1 papers (2021–2021)Jamie A. Moroco · Northeastern University1 papers (2021–2021) · 1 papers (2021–2021)Dale Porter · Beaumont Hospital1 papers (2021–2021) · 1 papers (2021–2021)Zachary Mullin-Bernstein · Northeastern University1 papers (2021–2021) · 1 papers (2021–2021)Florence F. Wagner · University of Colorado Denver1 papers (2021–2021) · 1 papers (2021–2021)Patrick McCarren · Novartis (Switzerland)1 papers (2021–2021)William R. Sellers · Broad Institute1 papers (2021–2021)Ritu Singh · University of California, Davis1 papers (2021–2021) · 1 papers (2021–2021)